Ultrafiltration and subsequent high performance liquid chromatography for in vivo determinations of the protein binding of etoposide

Cancer Letters

Volumn 106, Issue 1, 1996, Pages 91-96

  Liliemark, Eva ^a   Herngren, Lars ^b   Pettersson, Birgitta ^a   Peterson, Curt ^a   Liliemark, Jan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Löwenström Hospital   (Sweden)

Author keywords

Equilibrium dialysis; Etoposide; High performance liquid chromatography; Protein binding; Ultrafiltration

Indexed keywords

DRUG METABOLITE; ETOPOSIDE; PLASMA PROTEIN; TENIPOSIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; EQUILIBRIUM DIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; PLASMA; PRIORITY JOURNAL; TEMPERATURE; ULTRAFILTRATION;

EID: 0030598965     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/0304-3835(96)04307-8     Document Type: Article

References (13)

1. [1] O'Dwyer, P., Leyland-Jones, B., Alonso, M., Marsoni, S. and Wittes, R. (1985) Etoposide (VP-16-213): current status of an active anticancer drug. N. Engl. J. Med., 312, 692-700.
2. [2] Stadtmauer, E., Cassileth, P. and Gale, R. (1989) Etoposide in leukemia, lymphoma and bone marrow transplantation. Leukemia Res., 13, 639-650.
3. [3] Belani, C., Doyle, L. and Aisner, J. (1994) Etoposide: current status and future perspectives in the management of malignant neoplasms. Cancer Chemother. Pharmacol., 34, S118-S126.
4. [4] Maanen, J.v., Retél, J., Vries, J.d. and Pinedo, H. (1988) Mechanism of action of antitumor drug etoposide: a review. J. Natl. Cancer Inst., 80, 1526-1533.
5. [5] Long, B.H. (1992) Mechanism of action of teniposide (VM-26) and comparison with etoposide (VP-16). Semin. Oncol., 2, 3-19.
6. [6] Allen, L. and Creaven, P. (1975) Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. Eur. J. Cancer, 11, 697-707.
7. [7] Stewart, C., Arbuck, S., Fleming, R. and Evans, W. (1991) Relation of systemic exposure to unbound etoposide and hematologic toxicity. Clin. Pharmacol. Ther., 50, 385-393.
8. [8] Stewart, C., Pieper, J., Arbuck, S. and Evans, W. (1989) Altered protein binding of etoposide in patients with cancer. Clin. Pharmacol. Ther., 45, 49-55.
9. [9] Stewart, C., Arbuck, S., Fleming, R. and Evans, W. (1990) Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. J. Clin. Oncol., 8, 1874-1879.
10. [10] Schwinghammer, T., Fleming, R., Rosenfeld, C., Przepiorka, D., Shadduck, R., Bloom, E. and Stewart, C. (1993) Disposition of total and unbound etoposide following high-dose therapy. Cancer Chemother. Pharmacol., 32, 273-278.
11. [11] Strife, R., Jardine, I. and Colvin, M. (1980) Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography. J. Chromatogr., 182, 211-220.
12. [12] Liliemark, E.K., Liliemark, J., Peterson, B., Gruber, A., Björkholm, M. and Peterson, C. (1993) In vivo accumulation of etoposide in peripheral leukemic cells in patients treated for acute myeloblastic leukemia: relation to plasma concentrations and protein binding. Leukemia Lymphoma, 10, 323-328.
13. [13] Liliemark, E., Pettersson, B., Peterson, C. and Liliemark, J. (1995) High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukemic cells. J. Chromatogr. B, Biomed. Appl., 669, 311-317.